Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a biotechnology startup that is making significant strides in the field of RNA therapeutics. The company's focus lies in developing innovative therapies, including cell and gene therapies, to address a wide range of diseases such as rare and genetic disorders, as well as aging-related issues. They have three key technologies driving their advancements. Their Bobcat mRNA™ technology has demonstrated promising preclinical results in restoring muscular function in models of Duchenne muscular dystrophy, without any associated safety concerns. Another technology, controllable self-replicating (c-srRNA™), aims to improve efficacy by controlling gene expression and reducing off-target effects. Additionally, their ZSCAN4 technology is being tested in a Phase 1/2 clinical trial to extend telomeres in patients with telomere biology disorders, showing initial signs of potential success. Elixirgen Therapeutics, founded in 2017, recently secured a $7.00M Venture Round investment in November 2023, indicating a continued interest from investors in the company's potential. This Baltimore-based company operates from the Science + Technology Park at Johns Hopkins. Elixirgen Therapeutics is certainly a company to watch as it continues to reimagine the power of RNA in therapeutic innovations.